OptimizeRx Reports Record Q4 Profit, 19% FY Revenue Growth, and $10M Share Buyback
summarizeSummary
OptimizeRx reported robust fourth quarter and full-year 2025 financial results, highlighted by record GAAP net income of $5.0 million for Q4 and $5.1 million for the full year, a significant turnaround from prior year losses. Full-year revenue increased 19% to $109.4 million, and Adjusted EBITDA reached $24.3 million, demonstrating strong profitable growth and achieving the "Rule of 40" benchmark. The company also updated its 2026 revenue guidance to $109-$114 million and adjusted EBITDA guidance to $21-$25 million, signaling continued confidence. Further bolstering shareholder value, the Board authorized a $10 million share repurchase program, which is a material capital allocation decision for a company of its size. Traders will be watching for continued execution on guidance and the impact of the share repurchase program, especially given potential market volatility and MFN pricing uncertainty mentioned by management.
في وقت هذا الإعلان، كان OPRX يتداول عند ٧٫٨٣ US$ في NASDAQ ضمن قطاع Life Sciences، مع قيمة سوقية تقارب ١٤٠٫٤ مليون US$. تراوح نطاق التداول خلال 52 أسبوعًا بين ٣٫٩٩ US$ و٢٢٫٢٥ US$. تم تقييم هذا الخبر على أنه ذو معنويات سوقية إيجابية وبدرجة أهمية ٩ من 10. المصدر: GlobeNewswire.